AKRO

Akero Therapeutics, Inc. [AKRO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

AKRO Stock Summary

Top 10 Correlated ETFs

AKRO

Top 10 Correlated Stocks

AKRO

In the News

AKRO Financial details

Company Rating
-
Market Cap
1.53B
Income
-149.29M
Revenue
284K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
55
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-11.19
Forward P/E
-
PEG
-312.2
P/S
-
P/B
2.2
P/C
-
P/FCF
-10.51
Quick Ratio
19.5
Current Ratio
20.25
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.8
EPS next Y
-
EPS next Q
-
EPS this Y
3.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
39.44%
-
-
-
-
SMA20
32.54%
SMA50
27.1%
SMA100
122.5%
Inst Own
-
Inst Trans
-
ROA
-18%
ROE
-25%
ROC
-0.22%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
11.25-58.38
52W High
-4.1%
52W Low
+405.64%
RSI
69.43
Rel Volume
1.52
Avg Volume
1.39M
Volume
2.11M
Perf Week
4.96%
Perf Month
22.75%
Perf Quarter
93.73%
Perf Half Y
83.26%
-
-
-
-
Beta
-0.371
-
-
Volatility
0.79%, 5.6%
Prev Close
3.85%
Price
55.62
Change
5.92%

Something similar

Top by Market Cap
AMZN
META
MIX.JO
1YD.DE
V
Top Correlated ETFs
ESGO.L
ESGP.L
GDIG.L
SIL
FID
Top Correlated Stocks
TRT.L
NGD
BTG
NVS
IDYA
Similar Market Cap
SCL
VBAL.TO
TGLS
002862.SZ
RVLV

Company Profile

Healthcare Biotechnology
  • Volume Average 1.39M
  • Market Capitalization 1.53B
  • Employee 55
  • CEO Dr. Andrew Cheng M.D., Ph.D.
  • Headquarters South San Francisco,CA,US
  • IPO Date 2019-06-20
  • Website https://www.akerotx.com

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.